Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
126 results about "Metabolomic profiling" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Metabolomic profiling of prostate cancer
InactiveUS20090075284A1High throughput methodMicrobiological testing/measurementBiological testingMetaboliteProstate cancer
Owner:METABOLON +1
Simulative-target metabonomics analytic method based on combination of liquid chromatography and mass spectrum
ActiveCN104297355AWide detection linear rangeMeet detectionComponent separationMetaboliteRetention time
The invention provides a simulative-target metabonomics analytic method based on combination of liquid chromatography and mass spectrum. The method includes following steps: respectively manufacturing to-be-analyzed samples into merged samples according to groups; automatically collecting secondary mass spectrums of metabolites in each merged samples through data of UHPLS / Q-TOF MS with dependence on a collecting mode; extracting a retaining time and information of parent ions and daughter ions of the metabolites by qualitative analytic software; screening out characteristic ion pair information of the metabolites according to daughter ion response intensity; summing the characteristic ion pair information of each merged samples; and scanning the obtained characteristic ion pair of the metabolites by UHPLC / QQQ MS through a dynamic multi-reaction monitoring mode in an actual sample for obtaining a corresponding spectrogram; and performing integration through quantitative analytic software to obtain the metabolites in the to-be-analyzed samples and content information thereof.
Owner:DALIAN INST OF CHEM PHYSICS CHINESE ACAD OF SCI
Method for simultaneous extraction and analysis of metabolite group and lipid group in microtissue
The invention discloses a method for simultaneous extraction and analysis of a metabolite group and a lipid group in microtissue. The method comprises the following steps: freeze drying to-be-analyzed microtissue, accurately weighing 1 to 25 mg of the freeze-dried microtissue and adding solvents like methanol (MeOH), methyl tert butyl ether (MTBE) and water in certain proportion for extraction; allowing a solution obtained after completion of extraction to be divided into two layers, wherein an upper layer mainly contains nonpolar metabolites and lipids, and the lower layer mainly comprises polar and medium-polar metabolites; and subjecting the upper-layer solution and the lower-layer solution to mixing in proportion and freeze-drying, then carrying out redissolving and then metabonomical analysis based on liquid chromatography-mass spectrometry, subjecting the upper-layer solution to freeze-drying and then to redissolving and carrying out lipidomical analysis based on liquid chromatography-mass spectrometry. The method has the following advantages: metabolites and lipids are extracted as many as possible through one extraction of a small amount of tissue, and through metabonomical and lipidomical analysis, the amount of a tissue sample is saved, which benefits other biochemical analysis of the tissue sample.
Owner:DALIAN INST OF CHEM PHYSICS CHINESE ACAD OF SCI
Serum specificity metabolite spectrum for patient with lung cancer, and building method thereof
ActiveCN103616450AEasy to handleStrong qualitative analysis abilityComponent separationGas phaseOriginal data
Owner:HUZHOU CENT HOSPITAL
Lung cancer early diagnostic marker based on metabonomics and artificial intelligence technology and application thereof
ActiveCN109884302AFacilitate early diagnosis and treatmentGood effectComponent separationMedical automated diagnosisMetaboliteScreening method
The invention discloses a lung cancer early diagnostic marker based on metabonomics and a screening method thereof. The diagnostic marker comprises any one or combination of various markers in 25 plasma metabolism markers. The invention also provides a method for establishing a diagnostic model through utilization of the lung cancer early diagnostic marker and application of the lung cancer earlydiagnostic marker in a diagnostic kit. According to the lung cancer early diagnostic marker, the methods and the application, through utilization of a high performance liquid chromatography-mass spectrometry, non-target metabonomics analysis is carried out on plasma of patients; through utilization of an artificial intelligence data analysis technology, different metabolite between lung cancer patients and normal people is discovered; and further through target metabonomics analysis and machine learning modeling, diagnostic capability of specificity different metabolite, namely, the lung cancer early diagnostic marker in lung cancer early diagnosis is verified.
Owner:北京博远精准医疗科技有限公司
Method For Normalization in Metabolomics Analysis Methods with Endogenous Reference Metabolites.
The present invention relates to the use of endogenous reference metabolites and a method for normalization of intensity data corresponding to amounts and / or concentrations of selected target metabolites in a biological sample of a mammalian subject, wherein said intensity data are obtained by a metabolomics analysis method with one or a plurality of endogenous reference metabolites, comprising carrying out at least one in vitro metabolomics analysis method of said selected target metabolites in said biological sample, simultaneously carrying out in the same sample a quantitative analysis of one or a plurality of endogenous reference metabolites or derivatives thereof, wherein said endogenous reference metabolites are such compounds in the biological sample which are present in the subject at an essentially constant level; and wherein said endogenous reference metabolites or derivatives thereof have a molecular mass less than 1500 Da.
Owner:BIOCRATES LIFE SCIENCES AG
Test method for characterizing smoke exposure biological effect based on metabonomics
InactiveCN106814164ASimple and fast operationEase of evaluationComponent separationAnalysing gaseous mixturesEndogenous metabolismMetabolite
The invention discloses a test method for characterizing the biological effects of smoke exposure based on metabolomics. The test method adopts the metabolomics analysis method, and the biomarker groups related to the biological effects of smoke exposure are tested in different drug administration groups. The changes between groups are used to characterize the biological responses of experimental animals placed in the smoke exposure environment. The present invention is easy to operate, and evaluates the influence of mainstream smoke on endogenous metabolites in rats, and compares the similarities and differences between the effects of natural herbal added tobacco and ordinary cigarettes on endogenous metabolites, in order to evaluate the harm reduction effect of cigarettes and its associated mechanisms provide a reliable tool.
Owner:CHINA TOBACCO JIANGXI IND CO LTD
Method, apparatus and computer program product for metabolomics analysis
A method is provided for analyzing metabolite data in a sample, comprising analyzing a sample to determine a first number of metabolites, and amount of each metabolite, included in the sample, and a second number of the first number of metabolites that are regulated. Biochemical pathways are determined, each having a third number of the first number of metabolites that are included in the sample and in the determined biochemical pathway. For each of the determined biochemical pathways having the third number of metabolites, a fourth number of the second number of metabolites that are included in the sample and in the determined biochemical pathway that are regulated metabolites is determined. Each of the third number of metabolites within one of the determined biochemical pathways is displayed and distinguished by the amount of each corresponding metabolite included in the sample. An associated apparatus and computer program product are also provided.
Owner:METABOLON
Metabolomics-based pancreatic cancer diagnosis marker as well as screening method and application thereof
ActiveCN110646554AHigh sensitivityWith clinical useComponent separationPancreas CancersScreening method
The invention discloses a metabolomics-based pancreatic cancer diagnosis marker and a screening method thereof. The diagnosis marker comprises any one or a combination of more of 31 plasma metabolic markers. The invention also provides a method for constructing a diagnosis model by using the pancreatic cancer diagnosis marker and an application in a diagnosis kit. According to the method, non-target metabolomics analysis is carried out on the plasma of a patient through a high-efficiency liquid chromatography mass spectrometry technology, the difference metabolite between the pancreatic cancerpatient and the normal people is found through an artificial intelligence data analysis technology, and the diagnosis capability of the specific differential metabolite, namely the pancreatic cancerdiagnosis marker in the diagnosis of the pancreatic cancer is further verified through target metabolomics analysis and machine learning modeling.
Owner:北京博远精准医疗科技有限公司
Use of biomarker in preparation of heart failure diagnosis composition and diagnosis device
InactiveCN104515860AComponent separationMaterial analysis by electric/magnetic meansButyrylcarnitineMetabolomic profiling
A method for diagnosing heart failure in a subject is provided. The method includes steps of measuring a biological sample of the subject to obtain an amount of at least one biomarker selected from the group consisting of xanthine, spermidine, propionylcarnitine, butyrylcarnitine and P-cresyl sulfate; and comparing the amount of the at least one biomarker to a reference. Moreover, the present invention relates to a method for staging heart failure or evaluating a prognosis of heart failure in a subject.
Owner:CHANG GUNG UNIVERSITY +1
Pancreatic ductal adenocarcinoma marker and screening method thereof
ActiveCN109239210AImprove diagnosis rateAccurately reflect differences in metabolic profilesComponent separationPancreas Ductal AdenocarcinomaMetabolite
The invention discloses a pancreatic ductal adenocarcinoma marker and a screening method thereof, which belongs to the field of clinical test and diagnosis. In view of the problem that the detection sensitivity and the detection specificity of the existing pancreatic ductal adenocarcinoma diagnosis marker are poor, serum of an early patient of early stage pancreatic duct adenocarcinoma is subjected to a trace metabolomics analysis by the high-performance liquid chromatography-tandem mass spectrometry technology, and different metabolites between normal human and the early stage pancreatic ductal adenocarcinoma patients are found. The different metabolites between normal human and pancreatic ductal adenocarcinoma patients are further analyzed by this technique to find the specific differentmetabolites C10:1 acyl carnitine and lysophosphatidyl choline LysoPC (14:0) of pancreatic ductal adenocarcinoma patients caused by cancer, i.e., the diagnostic molecules of the pancreatic ductal adenocarcinoma. According to the pancreatic ductal adenocarcinoma marker and the screening method thereof, the method can assist CA19-9 in diagnosing pancreatic duct adenocarcinoma patients, and can improve the diagnosis rate for the CA19-9 negative patients by 85%. The method is suitable for the screening of tumor markers.
Owner:HARBIN INST OF TECH
Metabolism group method for distinguishing false positive mass spectra peak signals and quantificationally correcting mass spectra peak area
ActiveCN106018600AEasy to filterSimple Metabolomics StudyComponent separationGroup studySample dilution
The invention discloses a metabolism group method for distinguishing false positive mass spectra peak signals and quantificationally correcting mass spectra peak area. The invention provides a metabolism group study method; by the method, the biological source and non-biological source mass spectra peak signals can be effectively distinguished; the mass spectra peak signals are quantificationally evaluated; the mass spectra peaks with poor quantification performance are excluded; through QC sample dilution, a relative content correction model is built; the mass spectra peak area is corrected. The method has the maximum characteristics that the false positive mass spectra signals can be effectively eliminated, so that the metabolism group data becomes reliable; the real biomarkers can be favorably screened. The method can aim at plant, animal and microbe samples; the method can also be suitable for the mass-spectra-platform-based metabolism group analysis of GC-MS, LC-MS and CE-MS.
Owner:INST OF BOTANY CHINESE ACAD OF SCI
Targeting qualitative and quantitative metabonomic analysis method used for screening cancer biomarkers based on LC-MS/MS technology
The invention relates to a targeting qualitative and quantitative metabonomic technical analysis method used for screening cancer biomarkers based on the LC-MS / MS technology. The method is characterized in that a structure prediction function of multi-reaction monitoring-dependent information acquisition-enhanced daughter ion detection on correlative metabolites and a structure identification function of a high-resolution mass spectrum are predicted by fully utilizing a multi-reaction monitoring quantitation function of the high performance liquid-tandem mass spectrum, and the analysis methodsuitable for screening biomarkers of various cancers is formed. The method has the advantages of high flux, good stability and high adaptability, and improves sensitivity and accuracy of screening andfinding of metabonomic biomarkers.
Owner:INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
Metabonomics analysis method base on acute anaphylactic reaction
ActiveCN103235073AOvercome subjectivityOvercoming sensitivityComponent separationHypersensitive responseMetabolome
The invention discloses a metabonomics analysis method base on acute anaphylactic reaction. The invention mainly starts from the systems biology, and applies a UPLC-QTof / MS technology platform for UPLC and SPE-RRLC-Q-TOF combination, and establishes an acute anaphylactic reaction guinea pig serum metabonomics evaluation model, and provides a basis for further research of medicament acute anaphylactic reaction. During analysis, the UPLC and SPE-RRLC-Q-TOF combination technology is used for detecting serum samples of normal guinea pig and experiment guinea pig with acute anaphylactic reaction generated by induction, and a metabolome spectrogram is obtained by an acquisition method after optimization, and a mode identification method suitable for evaluating animal acute anaphylactic reaction is established for analyzing the metabolome data, which establishes a base for subsequently and furtherly screening biological tag with characteristics and developing a new animal acute anaphylactic reaction detection method.
Owner:HUNAN INST FOR FOOD & DRUG CONTROL
Method for screening specific serum metabolism markers for triple-negative breast cancer
ActiveCN105738526AEffective early diagnosis targetComponent separationOmicsMetaboliteLymphatic Spread
The invention discloses a method for screening specific serum metabolism markers for triple-negative breast cancer. The method includes respectively carrying out metabonomics analysis on serum samples of experimental groups A and control groups B by the aid of LC / MS (liquid chromatography / mass spectrometry) instruments; carrying out model discriminant analysis on response intensity data of peaks of substances in the samples; respectively carrying out PCA (principal component analysis) on the experimental groups A and the control groups B; building PLS-DA (partial least square- discriminant analysis) and OPLS-DA (orthogonal partial least square-discriminant analysis) models on the basis so as to obtain difference expression metabolites; screening and identifying the biological markers related to breast cancer carcinogenesis and metastasis. The biological markers include hemolytic lecithin, sphingomyelin and small-molecule amino acid. The method has the advantages that results obtained by the aid of the method have an important significance on illustrating change rules of contents of characteristic metabolites in the serum of patients who suffer from the triple-negative breast cancer and illustrating effects of the metabolites in tumor formation and development procedures; effective breast cancer early diagnosis target sites can be acquired by the aid of the method, and data bases can be provided for establishing specific cancer diagnosis models.
Owner:重庆韦钚医药科技有限公司
Differential expression profile model of hepatitis B virus (HBV) infectivity and alcoholic cirrhosis, and construction method thereof
The invention relates to a construction method for a differential expression profile model of hepatitis B virus (HBV) infectivity and alcoholic cirrhosis. According to the method, peripheral blood samples of liver cirrhosis patients with HBV infections, alcoholic cirrhosis patients and healthy people are sampled to carry out nulcear magnetic resonance analysis, then a multi-variable statistical analysis is adopted for the resulting spectrograms from the nulcear magnetic resonance analysis to obtain the differential expression profile model of the HBV infectivity and the alcoholic cirrhosis. According to the present invention, the metabonomics analysis method is adopted for analyzing the metabolic products of the liver cirrhosis patients with HBV infections, the alcoholic cirrhosis patients and the healthy people, such that the specific metabolic products related to the pathologic mechanisms of the liver cirrhosis with the HBV infection and the alcoholic cirrhosis are found, the differential expression profile model of the HBV infectivity and the alcoholic cirrhosis is constructed; such that a support is provided for specific diagnosis and treatment of the liver cirrhosis with the HBV infection and the alcoholic cirrhosis. In addition, the invention further relates to a differential expression profile model of the HBV infectivity and the alcoholic cirrhosis.
Owner:CHONGQING MEDICAL UNIVERSITY
Method for analyzing Maca symbolic metabolite based on liquid chromatography-mass spectrometry metabonomics
The invention relates to a method for analyzing a Maca symbolic metabolite based on a liquid chromatography-mass spectrometry metabonomics. The method includes the steps: extracting the Maca metabolite by the aid of methyl alcohol, performing UHPLC-Q Exactive Orbitrap LC-MS analysis after preprocessing, processing data by the aid of a Compound Discover, leading the data in SIMCA14.0 software, analyzing the data by the aid of a principal component analysis (PCA) method, a partial least squares discriminant analysis (PLS-DA) method and an orthogonal-partial least squares discriminant analysis (OPLS-DA) method, and searching differential metabolites; inspecting effectiveness of PLS-DA model establishment by the aid of a substitution permutation inspection method. Results show that model establishment is effective. The analysis method is simple to operate, and Maca metabolites with different phenotypes are searched, so that the analysis method is used for distinguishing and identifying the Maca metabolites with different phenotypes.
Owner:YANTAI NEW ERA HEALTH IND
Method for constructing serum metabonomics analysis model
ActiveCN104713970AAchieve the purpose of early screeningA large amountComponent separationSerum samplesPrincipal component analysis
The invention discloses a method for constructing a serum metabonomics analysis model. The construction method comprises the following steps: collecting a healthy serum sample and an ill serum sample; performing LC-MS detection on the samples, thereby obtaining original metabolic fingerprints; preprocessing the fingerprints, sequentially performing principal component analysis and partial least square discriminant analysis on a two-dimensional matrix, thereby obtaining a PLS-DA model; and verifying the obtained PLS-DA model, wherein if the overfitting risk does not exist, the model construction is finished. According to the method disclosed by the invention, the serum metabonomics analysis technology is applied to early screening of an esophagus cancer, the high-risk population of the esophagus cancer can be rapidly and conveniently screened by virtue of model construction, the esophagus cancer screening range is widened, the entire population screening efficiency in the high incidence area of esophagus cancer is effectively improved, the screening cost is greatly reduced, pain of partial population caused by an invasive gastroscope is effectively avoided, and the method has significant economic and social benefits and is worthy of popularization and application.
Owner:SHANDONG TUMOR HOSPITAL
Metabolomic profiling of prostate cancer
The present invention relates to cancer markers. In particular, the present invention provides metabolites and panels of metabolites that are differentially present in cancer (e.g., prostate or breast cancer).
Owner:RGT UNIV OF MICHIGAN
Breast cancer diagnostic marker combination and application and determination method thereof
ActiveCN105675735AHigh sensitivityImprove clinical treatment effectComponent separationCysteine thiolateMetabolite
The present invention discloses a breast cancer diagnostic marker combination and application and a determination method thereof, and particularly relates to 13 difference metabolites (Aspartate, Glutamate, 5-Oxoproline, Cystine, Glutamine, Cysteine, Hypotaurine, Asparagine, Glycerolphosphate, Glycerophosphocholine, Arachidonate, Glyoxylate and pentosidine) and a combination thereof as a breast cancer early detection and diagnosis marker and application thereof and a determination method of the diagnosis marker, and the determination method is a metabonomic analysis method based on liquid / gas chromatography-mass spectrometry of plasma / serum of a patient with breast cancer. The diagnostic marker combination has the characteristics of high sensitivity and high specificity, has high sensitivity and specificity for early diagnosis of breast cancer, can be used for early detection of breast cancer, can gain time for patients to begin treatment as soon as possible, and improves clinical therapeutic effects.
Owner:HUMAN METABOLOMICS INST INC
Microwave assisted plasma sample pre-processing method and application in plasma metabonomics analysis
InactiveCN102680310AMeet processing requirementsMeet analysis needsComponent separationPreparing sample for investigationHigh energyVapor phase chromatography
The invention relates to the technical field of analytical chemistry and biological chemistry, the traditional plasma metabonomics sample pre-process is derived for 1 hour at 70 DEG C after oximation for 2 hours at 35 DEG C, the work is heavy, time-consuming and low-efficiency. The invention provides a sample pre-processing method of plasma oximation and derivatization assisted by microwave, which comprises the steps of: adding an oximation reaction reagent to the plasma sample, carrying out the oximation reaction under the condition of low-energy and short-time microwave; adding a derivatization reagent to carry out the derivatization reaction under the condition of high-energy and medium-time microwave. The invention also applies the processing method to the analysis of plasma metabonomics with a gas chromatograph-mass spectrometer. The method in the invention is applied to the process of the plasma treatment, the processing requirement of the sample and the requirement of the metabonomics analysis are met, the pre-processing time is shortened obviously, and the analysis efficiency is improved greatly.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Biomarker for preoperative identification of benign and malignant thyroid nodules, kit and application thereof
ActiveCN112684048AIncreased sensitivityImprove featuresComponent separationThyroid gland cancerBlood plasma
The invention relates to a biomarker for preoperative identification of benign and malignant thyroid nodules, a kit and application thereof. The level of 17 metabolites in peripheral blood plasma of a thyroid nodule patient is detected through metabonomics analysis, and omics analysis and a machine learning method are combined to construct a diagnosis model and evaluate the thyroid cancer diagnosis efficiency by using a subject working curve (ROC). The area of the metabolic marker combination diagnosis model composed of the metabolites under the ROC curve in thyroid nodule diagnosis can reach 95.05%, the sensitivity and specificity are both higher than 88%, and the metabolite marker combination diagnosis model can be applied to identification of thyroid benign and malignant nodules.
Owner:THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
Slow magic angle spinning nuclear magnetic resonance device and process for metabolomics profiling of tissues and biofluids
ActiveUS20130257432A1Enhances sample filling factorEliminate the effects ofManufacture of electrical instrumentsElectric/magnetic detectionMagic angle spinningTissue biopsy
A slow Magic-Angle Spinning NMR device and method are detailed that provide high resolution and high sensitivity metabolic profiling of biological samples. A new 1H-PASS sequence suppresses line broadening in the various biological samples. The device and method allow metabolic changes in small animals to be tracked through continuous investigations of minimally-invasive blood and tissue biopsy samples over a sustained period and allow intact biological objects with sizes up to a few centimeters to be studied.
Owner:BATTELLE MEMORIAL INST
Sample pretreatment method for plant metabolome analysis
ActiveCN105289773AReduce direct contactAvoid direct contactPreparing sample for investigationLaboratory glasswaresBiotechnologyPretreatment method
The invention discloses a sample pretreatment method for plant metabolome analysis. The method comprises the following steps: sampling and inactivating, sample homogenizing and grinding, centrifugal filtration and the like; various tissue parts are separately sampled, are frozen and inactivated quickly by adopting liquid nitrogen, and are homogenized and ground by high-speed oscillation in a liquid nitrogen environment; a mixed sample is extracted by adopting ultrasonic in an assistant manner after being obtained; finally, protein is removed through high-speed centrifugation. According to the sample pretreatment method, the defects of temperature change, easiness in pollution, serious sample waste, relatively poor repeatability, uneven sample mixing, relatively low work efficiency, high operating danger coefficient, high requirements on the proficiency and work experience of operating personnel and the like are overcome. The sample pretreatment method can be well applied to hard tissue sampling, homogenizing, grinding and extracting of woody plant samples of tea trees and the like, and is a rapid, nondestructive and pollution-free sample pretreatment technology for performing a metabonomics analysis test. The sample pretreatment method can also be applied to a quality component analysis, RNA (Ribonucleic Acid) extraction, a proteomics analysis and the like.
Owner:TEA RES INST CHINESE ACAD OF AGRI SCI
Method for analyzing influence of multi-dimensional nano material on cell metabonomics
PendingCN111751467AAccurately assess impactImpact Effective Comparative EvaluationComponent separationMicrobiological testing/measurementLiquid chromatography mass spectroscopyStatistical analysis
The invention relates to a method for analyzing influence of a multi-dimensional nano material on cell metabonomics. The analysis method for the influence of the multi-dimensional nano material on thecell metabonomics based on the liquid chromatography-mass spectrometry technology comprises the following steps: (1) co-culturing the multi-dimensional nano material and cells; (2) performing metabolite extraction; (3) carrying out liquid chromatography-mass spectrometry combined detection; and (4) performing bioinformatics statistical analysis. According to the metabonomics analysis method, theinteraction between the multi-dimensional nano material and cells is investigated, the cell metabolite is detected and analyzed, and the cell metabolite variety contents and the metabolic pathways under the effects of different multi-dimensional nanometer materials are compared so that the influence principle of the nanometer materials with different dimensions on the cell metabonomics is revealed, the basis is provided for the evaluation of the biological characteristics of the nanometer materials, and the application prospect is broad.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV
Method for detecting small-molecule metabolic markers in peripheral blood of aortic dissection, and its application
The invention relates to a method for detecting small-molecule metabolic markers in the peripheral blood of aortic dissection, and its application. Combined chromatography and mass spectrometry are employed for high-flux large-scale metabonomic analysis of patients with aortic dissection to determine small-molecule metabolic profiling of the peripheral blood of the aortic dissection, and three small-molecule metabolic markers with greatest difference is obtained, wherein the three small-molecule metabolic markers are N1-acetyl-N2-formyl-5-methoxy kynurenine, glycerophosphorylcholine and 2-mercaptohistidine betaine. The invention provides a simple, low-harm and cheap method for screening and diagnosis of aortic dissection, and effective reference bases can be provided for diagnosis of clinical patients and assessment of the treatment efficacy of drugs.
Owner:广东行海生物科技有限公司
Urine biomarker for Japanese schistosomiasis early diagnosis, screening method, and application
The invention discloses a urine biomarker for Japanese schistosomiasis early diagnosis. The urine biomarker is one or more of a xanthurenic acid, a naphthalenesulfonic acid, or enanthylcarnitine. Sensitivity and specificity of the marker are greater than 0.9, and an area under the curve (AUC) is greater than 0.9, indicating that the three indicators have better predictability and may be used for the Japanese schistosomiasis early diagnosis. The invention further discloses a metabolomics-based screening method for the urine biomarker for the Japanese schistosomiasis early diagnosis. By constructing a mouse Japanese schistosomiasis model, ultra performance liquid chromatography-tandem mass spectrometry is used to perform metabolomics analysis on mouse urine, and a characteristic differentialmetabolite, that is, the biomarker for the Japanese schistosomiasis early diagnosis, between a normal mouse and a Japanese schistosomiasis-infected mouse is found and analyzed. The screening method is non-invasive, convenient and fast, and can accurately reflect a metabolic spectrum difference between the Japanese schistosomiasis-infected mouse and the normal mouse and have high specificity.
Owner:SUN YAT SEN UNIV
Pancreatic cancer diagnostic marker combination as well as application and determination method thereof
ActiveCN105572276AImprove clinical treatment effectGood clinical effectComponent separationBetaineMetabolite
The invention discloses a pancreatic cancer diagnostic marker combination as well as application and a determination method thereof. The pancreatic cancer diagnostic marker combination comprises 15 differentiated metabolites (2,5-dihydroxybenzoic acid, talopyranose, proline, glutamate, choline, 1,5-anhydro-D-glucitol, tryptophan, glutamine, betaine, 2-oxoglutaric acid, methylguanidine, adenine, glycocholic acid, valine and 2-aminobutyric acid). The invention further provides a combination of the 15 differentiated metabolites to serve as a marker for early discovery and diagnosis of pancreatic cancer, application and a diagnostic marker determination method, and the method is a liquid-phase / gas-phase chromatography-mass spectrometry combined metabonomics analysis method based on plasma / serum of patients with pancreatic cancer. The pancreatic cancer diagnostic marker combination provided by the technical scheme of the invention has the characteristics of being high in sensitiveness and specificity, has relatively high sensitiveness and specificity on early pancreatic cancer diagnosis, can be used for early discovery of pancreatic cancer, gains time for the patients to receive treatment as soon as possible, and improves the clinical treatment effect.
Owner:麦特绘谱生物科技(上海)有限公司
Application of metabolic marker in atherosclerotic cerebral infarction
ActiveCN112305121AImprove the quality of lifeMaterial analysis using wave/particle radiationComponent separationMetaboliteBlood specimen
The invention discloses an application of a metabolic marker in atherosclerotic cerebral infarction, which comprises the following steps: collecting blood samples of atherosclerotic cerebral infarction and atherosclerotic patients, carrying out metabonomics analysis, and discovering metabolites with significant differences in two groups, therefore, the metabolite is utilized to predict early atherosclerotic cerebral infarction, and early treatment of a patient is further realized.
Owner:THE SECOND HOSPITAL OF HEBEI MEDICAL UNIV
Metabonomics and transcriptomics correlation analysis based method for screening key gene for synthesis of fritillaria alkaloid
InactiveCN108103176AIncrease alkaloid contentComponent separationMicrobiological testing/measurementCorrelation analysisAlkaloid
The invention discloses a metabonomics and transcriptomics correlation analysis based method for screening a key gene for the synthesis of fritillaria alkaloid. Specifically, the differential alkaloidand the content information of the differential alkaloid are obtained through the metabonomics analysis of three types of fritillaria, and meanwhile, the expression condition of the related gene in the synthetic route of the alkaloid is obtained through the functional annotation of the transcriptomics. The differential metabolin-gene dependence relation network is constructed through the correlation analysis, and the key gene for the synthetic route of the alkaloid, having a greater contribution to the content of the alkaloid in the fritillaria, is screened. The method provides important information for the further clarification of the synthesis mechanism of the alkaloid substance in the fritillaria, and provides an important evidence for increasing the content of fritillaria alkaloid bymeans of gene control and the like.
Owner:CHINA PHARM UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com